Effects of hormone therapy on blood pressure and the renin-angiotensin system in postmenopausal women

Minerva Cardioangiologica

Volumn 55, Issue 4, 2007, Pages 477-485

  Prime, D D ^a   Brosnihan, K B ^a   Herrington, D M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Blood pressure; Cerebrovascular accident; Estrogen replacement therapy; Heart, physiology; Hypertension; Postmenopause; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSINOGEN; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE; DROLOXIFENE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; MEDROXYPROGESTERONE ACETATE; MESSENGER RNA; PLACEBO; PROGESTERONE; RENIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; GENOTYPE; HEART INFARCTION; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; NONHUMAN; POSTMENOPAUSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE;

ANGIOTENSIN II; ANGIOTENSINOGEN; BLOOD PRESSURE; ESTROGEN REPLACEMENT THERAPY; FEMALE; GENOTYPE; HUMANS; POSTMENOPAUSE; RENAL CIRCULATION; RENIN; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 35948957892     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61.
2. Sourander L, Rajala T, Raiha I, Makinen J, Erkkola R, Helenius H. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 1998;352:1965-9.
3. Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 1991;164:489-94.
4. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
5. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288: 321-33.
6. nd ed. Abingdon: Taylor & Francis; 2005.p.351-73.
7. rd Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol 1995;75:264-8.
8. Kawano H, Motoyama T, Kugiyama K, Hirashima O, Ohgushi M, Fujii H et al. Gender difference in improvement of endothelium-dependent vasodilation after estrogen supplementation. J Am Coll Cardiol 1997;30: 914-9.
9. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation 1993;8:1816-28.
10. Blantz RC, Konnen KS, Tucker BJ. Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat. J Clin Invest 1976;57:419-34.
11. Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffiths R, Kumar AP et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A 2006;103:17985-90.
12. Steckelings U, Lebrun C, Qadri F, Veltmar A, Unger T Role of brain angiotensin in cardiovascular regulation. J Cardiovasc Pharmacol 1992;19 Suppl 6:S72-9.
13. Mitsube K, Mikuni M, Matousek M, Zackrisson U, Brannstrom M. Role of the angiotensin II system in regulation of ovulation and blood flow in the rat ovary. Reproduction 2003;125:425-35.
14. Taubman MB. Angiotensin II: a vasoactive hormone with ever-increasing biological roles. Circ Res 2003;92:9-11.
15. Campbell DJ, Habener JF. Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. J Clin Invest 1986;78:31-9.
16. Campbell DJ, Habener JF. Cellular localization of angiotensinogen gene expression in brown adipose tissue and mesentery: quantification of messenger ribonucleic acid abundance using hybridization in situ. Endocrinology 1987;121:1616-26.
17. Naftilan AJ, Zuo WM, Inglefinger J, Ryan TJ Jr, Pratt RE, Dzau VJ. Localization and differential regulation of angiotensinogen mRNA expression in the vessel wall. J Clin Invest 1991;87:1300-11.
18. Kunapuli SP, Kumar A. Molecular cloning of human angiotensinogen cDNA and evidence for the presence of its mRNA in rat heart. Circ Res 1987;60:786-90.
19. Hassager C, Riis BJ, Strom V, Guyene TT, Christiansen C. The long-term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure. Circulation 1987;76:753-8.
20. Schunkert H, Danser AH, Hense HW, Derkx FH, Kurzinger S, Riegger GA. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 1997;95:39-45.
21. White T, Ozel B, Jain JK, Stanczyk FZ. Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins. Contraception 2006;74:293-6.
22. Clauser E, Gaillard I, Wei L, Corvol P. Regulation of angiotensinogen gene. Am J Hypertens 1989;2(5 Pt 1):403-10.
23. Krattenmacher R, Knauthe R, Parczyk K, Walker A, Hilgenfeldt U, Fritzemeier KH. Estrogen action on hepatic synthesis of angiotensinogen and IGF-I: direct and indirect estrogen effects. J Steroid Biochem Mol Biol 1994;48:207-14.
24. Al KH, Nasrat H, Pipkin FB. A prospective, longitudinal study of the renin-angiotensin system, prostacyclin and thromboxane in the first trimester of normal human pregnancy: association with birthweight. Hum Reprod 2005;20:3157-62.
25. Ichikawa J, Sumino H, Ichikawa S, Ozaki M. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women. Am J Hypertens 2006;19: 744-9.
26. Seely EW, Brosnihan KB, Jeunemaitre X, Okamura K, Williams GH, Hollenberg NK et al. Effects of conjugated oestrogen and droloxifene on the renin-angiotensin system, blood pressure and renal blood flow in postmenopausal women. Clin Endocrinol (Oxf) 2004;60:315-21.
27. Proudler AJ, Cooper A, Whitehead M, Stevenson JC. Effects of oestrogen-only and oestrogen-progestogen replacement therapy upon circulating angiotensin I-converting enzyme activity in postmenopausal women. Clin Endocrinol (Oxf) 2003;58:30-5.
28. Nogawa N, Sumino H, Ichikawa S, Kumakura H, Takayama Y, Nakamura T et al. Effect of long-term hormone replacement therapy on angiotensin- converting enzyme activity and bradykinin in postmenopausal women with essential hypertension and normotensive postmenopausal women. Menopause 2001;8:210-5.
29. Sanada M, Higashi Y, Nakagawa K, Sasaki S, Kodama I, Tsuda M et al. Relationship between the angiotensin-converting enzyme genotype and the forearm vasodilator response to estrogen replacement therapy in postmenopausal women. J Am Coll Cardiol 2001;37:1529-35.
30. Sumino H, Ichikawa S, Ohyama Y, Nakamura T, Kanda T, Sakamoto H et al. Effects of hormone replacement therapy on serum angiotensin-converting enzyme activity and plasma bradykinin in postmenopausal women according to angiotensin-converting enzyme-genotype. Hypertens Res 2003;26:53-8.
31. Umeda M, Ichikawa S, Kanda T, Sumino H, Kobayashi I. Hormone replacement therapy increases plasma level of angiotensin II in postmenopausal hypertensive women. Am J Hypertens 2001;14:206-11.
32. Gallagher PE, Li P, Lenhart JR, Chappell MC, Brosnihan KB. Estrogen regulation of angiotensin-converting enzyme mRNA. Hypertension 1999;33(1 Pt 2):323-8.
33. Mombouli JV, Illiano S, Nagao T, Scott-Burden T, Vanhoutte PM. Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyperpolarizing factors. Circ Res 1992;71:137-44.
34. Yoshida H, Kusama Y, Kodani E, Yasutake M, Takano H, Atarashi H et al. Pharmacological preconditioning with bradykinin affords myocardial protection through NO-dependent mechanisms. Int Heart J 2005;46:877-87.
35. Neves LA, Averill DB, Ferrario CM, Aschner JL, Brosnihan KB. Vascular responses to Angiotensin-(1-7) during the estrous cycle. Endocrine 2004;24:161-5.
36. Maia LG, Ramos MC, Fernandes L, de Carvalho MH, Campagnole-Santos MJ, Souza dos Santos RA. Angiotensine-(1-7) antagonist A-779 attenuates the potentiation of bradykinin by captopril in rats. J Cardiovasc Pharmacol 2004;43:685-91.
37. Ferrario CM, Brosnihan KB, Diz DI, Jaiswal N, Khosla MC, Milsted A et al. Angiotensin-(1-7): a new hormone of the angiotensin system. Hypertension 1991;18(5 Suppl):III126-133.
38. Sumino H, Ichikawa S, Miya Y, Sakamaki T, Kurabayashi M. Angiotensin II plays an important role in maintaining blood pressure in postmenopausal women receiving hormone replacement therapy. Am J Hypertens 2005;18:1340-6.
39. Harvey PJ, Morris BL, Miller JA, Floras JS. Estradiol induces discordant angiotensin and blood pressure responses to orthostasis in healthy postmenopausal women. Hypertension 2005;45:399-405.
40. Paller MS, Gregorini G, Ferris TF. Pressor responsiveness in pseudopregnant and pregnant rats: role of maternal factors. Am J Physiol 1989;257(4 Pt 2):R866-R871.
41. Owonikoko TK, Fabucci ME, Brown PR, Nisar N, Hilton J, Mathews WB et al. In vivo investigation of estrogen regulation of adrenal and renal angiotensin (AT1) receptor expression by PET. J Nucl Med 2004;45:94-100.
42. Nickenig G, Baumer AT, Grohe C, Kahlert S, Strehlow K, Rosenkranz S et al. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 1998;97:2197-201.
43. Chasan-Taber L, Willett WC, Manson JE, Spiegelman D, Hunter DJ, Curhan G et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996;94:483-9.
44. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995;273:199-208.
45. Affinito P, Palomba S, Bonifacio M, Fontana D, Izzo R, Trimarco B et al. Effects of hormonal replacement therapy in postmenopausal hypertensive patients. Maturitas 2001;40:75-83.
46. Vongpatanasin W, Tuncel M, Mansour Y, Arbique D, Victor RG. Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. Circulation 2001;103:2903-8.
47. Ingelsson E, Bjorklund-Bodegard K, Lind L, Arnlov J, Sundstrom J. Diurnal blood pressure pattern and risk of congestive heart failure. JAMA 2006;295:2859-66.
48. Tsivgoulis G, Spengos K, Zakopoulos N. Diurnal blood pressure changes in stroke subtypes. Hypertension 2006;47:e26.
49. Cacciatore B, Paakkari I, Hasselblatt R, Nieminen MS, Toivonen J, Tikkanen MI et al. Randomized comparison between orally and transdermally administered hormone replacement therapy regimens of long-term effects on 24-hour ambulatory blood pressure in postmenopausal women. Am J Obstet Gynecol 2001;184: 904-9.
50. Sumino H, Ichikawa S, Kumakura H, Takayama Y, Kanda T, Sakamaki T et al. Effects of hormone replacement therapy on office and ambulatory blood pressure in Japanese hypertensive postmenopausal women. Hypertens Res 2003;26:369-76.
51. Lokkegaard E, Jovanovic Z, Heitmann BL, Keiding N, Ottesen B, Hundrup YA et al. Increased risk of stroke in hypertensive women using hormone therapy: analyses based on the Danish Nurse Study. Arch Neurol 2003;60:1379-84.
52. Holm P, Andersen HL, Andersen MR, Erhardtsen E, Stender S. The direct antiatherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium. A time course study in cholesterol-clamped rabbits. Circulation 1999;100: 1727-33.
53. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006;15:35-44.